Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy's To Market Amgen Therapies In India

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.

You may also be interested in...



Amgen-Dr Reddy's Build On India Alliance

Amgen is building on its alliance with Dr. Reddy’s Laboratories in India, shifting out certain products previously sold by GlaxoSmithKline in the country to the Hyderabad-based firm.

Amgen's Repatha India Trial Waiver Plan Trips Up

Amgen's PCSK9 inhibitor Repatha, already constrained by payor pushbacks on prices in the West and awaiting outcomes data, now appears to be facing a challenge in India. A key Indian expert panel has turned down Amgen's request for a trial waiver for evolocumab, a move that could hold up launch plans with partner Dr Reddy's.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel